Lipoic acid in secondary progressive MS: A randomized controlled pilot trial
This randomized controlled pilot trial evaluated the effects of lipoic acid (LA) supplementation in patients with secondary progressive multiple sclerosis (SPMS). Fifty-one participants aged 40 to 70 with an EDSS score between 4.0 and 6.5 received either 1,200 mg of LA daily or a placebo for two years. The study
June 26, 2025
No Comments